<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-66818</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Autologous hematopoietic stem cell transplantation folowed by oral bexarotene in a patient with advanced mycosis fungoides</dc:title>
<dc:description xml:lang="en">We describe the case of a 17-year-old patient with rapidly progressing and aggressive mycosis fungoides, with multiple cutaneous tumors and large cell transformation. She was initially treated with 3 cycles of high-dose chemotherapy with mega-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) without response, leading to the decision to undertake autologous hematopoietic stem cell transplantation. Partial remission of the disease was achieved with this treatment and subsequent introduction of oral bexarotene led to complete remission, which has been maintained for more than 3 years with good tolerance of oral therapy. We discuss the advantages and disadvantages of autologous hematopoietic stem cell transplantation and the use of oral bexarotene (AU)</dc:description>
<dc:creator>Izu, R</dc:creator>
<dc:creator>Díaz-Pérez, JL</dc:creator>
<dc:creator>Acebo, E</dc:creator>
<dc:creator>Pérez-Barrio, S</dc:creator>
<dc:creator>García-Ruiz, JC</dc:creator>
<dc:creator>Martínez de Lagrán, Z</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Exponemos el caso de una paciente de 17 años que presentó una micosis fungoide de evolución rápida y agresiva, con múltiples tumores cutáneos y transformación fenotípica celular a linfoma de células grandes. Fue tratada inicialmente con 3 ciclos de quimioterapia en dosis altas (MEGA-CHOP) sin respuesta, por lo que se decidió realizar un trasplante autólogo de progenitores hematopoyéticos. Este tratamiento consiguió una remisión parcial de la enfermedad, y con la posterior introducción del bexaroteno oral se logró la remisión completa, que se ha mantenido durante más de 3 años con muy buena tolerancia al bexaroteno oral. Analizamos las ventajas y desventajas de la utilización del trasplante autólogo de progenitores hematopoyéticos y del uso de bexaroteno oral (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;99(7): 560-564, sept. 2008. ilus</dc:source>
<dc:identifier>ibc-66818</dc:identifier>
<dc:title xml:lang="es">Trasplante autólogo de progenitores hematopoyéticos seguido de bexaroteno oral en paciente con micosis fungoide avanzada</dc:title>
<dc:subject>^d29459^s22016</dc:subject>
<dc:subject>^d14573^s22045</dc:subject>
<dc:subject>^d13259^s22009</dc:subject>
<dc:subject>^d10867^s22073</dc:subject>
<dc:subject>^d14573^s22074</dc:subject>
<dc:subject>^d14573^s22031</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23473^s22053</dc:subject>
<dc:subject>^d32857^s22074</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d29459^s22009</dc:subject>
<dc:subject>^d3540^s22073</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d13259^s22080</dc:subject>
<dc:subject>^d30385^s22073</dc:subject>
<dc:subject>^d10430^s22012</dc:subject>
<dc:subject>^d6547^s22073</dc:subject>
<dc:subject>^d23473^s22071</dc:subject>
<dc:type>article</dc:type>
<dc:date>200809</dc:date>
</metadata>
</record>
</ibecs-document>
